Download PDF
Semin Vasc Med 2003; 03(4): 363-374
DOI: 10.1055/s-2004-815694
RISK STRATIFICATION

Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Troponins in Acute Coronary Syndromes

Benjamin M. Scirica, David A. Morrow
  • Cardiovascular Division, Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA
Further Information

Publication History

Publication Date:
03 February 2004 (online)

    Permissions and Reprints

ABSTRACT

Delivering superior clinical specificity and sensitivity for myocardial necrosis, cardiac troponin has replaced creatine kinase-MB as the preferred biomarker for establishing the diagnosis of myocardial infarction. On the basis of expert recommendations, present convention sets the diagnostic decision-limit for each assay at the 99th percentile of troponin levels in an apparently healthy reference population. Owing to a lack of standardization between different assays, this level, corresponding to the 99th percentile, will vary depending upon the manufacturer. Among patients presenting with an acute coronary syndrome (ACS), even low-level elevations of cardiac troponin T or I are associated with higher risk of death and recurrent ischemic events compared with patients with a troponin level below the appropriate decision limit. Renal failure does not appear to diminish the prognostic value of troponins among patients with a high clinical probability of ACS. In addition, patients with elevated levels of troponin appear to gain the most benefit from more aggressive medical therapy with antithrombin and antiplatelet medications as well as an early invasive management strategy. Cardiac troponins offer extremely high tissue specificity but do not discriminate between ischemic and nonischemic mechanisms of myocardial injury; thus, presently the clinician must assess whether a patient's presenting symptoms are consistent with ACS. It is possible that future generations of troponin assays will detect specific post-translational modifications of troponins that may increase the analytic sensitivity for myocardial damage and offer insight into the timing and mechanism of myocardial injury.

KEYWORDS

Troponin - acute coronary syndrome - prognosis - biomarkers

REFERENCES

  • 1 Hamm C W, Braunwald E. A classification of unstable angina revisited.  Circulation . 2000;  102 118-122
    CrossrefPubMedGoogle Scholar
  • 2 Scirica B M, Cannon C P, Antman E M. et al . Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry.  Am J Cardiol . 2002;  90 303-305
    CrossrefPubMedGoogle Scholar
  • 3 Cannon C P. Evidence-based risk stratification to target therapies in acute coronary syndromes.  Circulation . 2002;  106 1588-1591
    CrossrefPubMedGoogle Scholar
  • 4 Braunwald E, Antman E M, Beasley J W. et al . ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina).  J Am Coll Cardiol . 2002;  40 1366-1374
    CrossrefPubMedGoogle Scholar
  • 5 Morrow D A. Troponins in patients with acute coronary syndromes: biologic, diagnostic, and therapeutic implications.  Cardiovasc Toxicol . 2001;  1 105-110
    PubMedGoogle Scholar
  • 6 Morrow D A, Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy.  Circulation . 2003;  108 250-252
    CrossrefPubMedGoogle Scholar
  • 7 Ross R. Atherosclerosis-an inflammatory disease.  N Engl J Med . 1999;  340 115-126
    CrossrefPubMedGoogle Scholar
  • 8 Libby P. Current concepts of the pathogenesis of the acute coronary syndromes.  Circulation . 2001;  104 365-372
    CrossrefPubMedGoogle Scholar
  • 9 Hamm C W, Ravkilde J, Gerhardt W. et al . The prognostic value of serum troponin T in unstable angina.  N Engl J Med . 1992;  327 146-150
    PubMedGoogle Scholar
  • 10 Ahmed S A, Williamson J R, Roberts R, Clark R E, Sobel B E. The association of increased plasma MB CPK activity and irreversible ischemic myocardial injury in the dog.  Circulation . 1976;  54 187-193
    PubMedGoogle Scholar
  • 11 Ishikawa Y, Saffitz J E, Mealman T L, Grace A M, Roberts R. Reversible myocardial ischemic injury is not associated with increased creatine kinase activity in plasma.  Clin Chem . 1997;  43 467-475
    PubMedGoogle Scholar
  • 12 Wu A H, Ford L. Release of cardiac troponin in acute coronary syndromes: ischemia or necrosis?.  Clin Chim Acta . 1999;  284 161-174
    CrossrefPubMedGoogle Scholar
  • 13 Chocron S, Alwan K, Toubin G. et al . Effects of myocardial ischemia on the release of cardiac troponin I in isolated rat hearts.  J Thorac Cardiovasc Surg . 1996;  112 508-513
    PubMedGoogle Scholar
  • 14 Chen Y, Serfass R C, Mackey-Bojack S M, Kelly K L, Titus J L, Apple F S. Cardiac troponin T alterations in myocardium and serum of rats after stressful, prolonged intense exercise.  J Appl Physiol . 2000;  88 1749-1755
    PubMedGoogle Scholar
  • 15 Antman E M, Grudzien C, Mitchell R N, Sacks D B. Detection of unsuspected myocardial necrosis by rapid bedside assay for cardiac troponin T.  Am Heart J . 1997;  133 596-598
    PubMedGoogle Scholar
  • 16 Carlson R J, Navone A, McConnell J P. et al . Effect of myocardial ischemia on cardiac troponin I and T.  Am J Cardiol . 2002;  89 224-226
    CrossrefPubMedGoogle Scholar
  • 17 Thayapran N, Prigent F, Steingart R, Feng Y J, Lowenkron D, Wu A H. Is there a release of cardiac troponin during exercise testing?.  (abstract). Circulation . 1997;  96 I-461
    PubMedGoogle Scholar
  • 18 Kwong R Y, Schussheim A E, Rekhraj S. et al . Detecting acute coronary syndrome in the emergency department with cardiac magnetic resonance imaging.  Circulation . 2003;  107 531-537
    CrossrefPubMedGoogle Scholar
  • 19 Jaffe A S, Ravkilde J, Roberts R. et al . It's time for a change to a troponin standard.  Circulation . 2000;  102 1216-1220
    CrossrefPubMedGoogle Scholar
  • 20 The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction.  J Am Coll Cardiol . 2000;  36 959-969
    CrossrefPubMedGoogle Scholar
  • 21 Shi Q, Ling M, Zhang X. et al . Degradation of cardiac troponin I in serum complicates comparisons of cardiac troponin I assays.  Clin Chem . 1999;  45 1018-1025
    PubMedGoogle Scholar
  • 22 Morrow D A, Rifai N, Tanasijevic M J, Wybenga D R, de Lemos A J, Antman E M. Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI) 11B substudy.  Clin Chem . 2000;  46 453-460
    PubMedGoogle Scholar
  • 23 Labugger R, Organ L, Collier C, Atar D, Van Eyk E J. Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction.  Circulation . 2000;  102 1221-1226
    CrossrefPubMedGoogle Scholar
  • 24 Katrukha A G, Bereznikova A V, Filatov V L. et al . Degradation of cardiac troponin I: implication for reliable immunodetection.  Clin Chem . 1998;  44 2433-2440
    PubMedGoogle Scholar
  • 25 Heidenreich P A, Alloggiamento T, Melsop K, McDonald K M, Go A S, Hlatky M A. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis.  J Am Coll Cardiol . 2001;  38 478-485
    CrossrefPubMedGoogle Scholar
  • 26 Heeschen C, Hamm C W, Bruemmer J, Simoons M L. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial.  J Am Coll Cardiol . 2000;  35 1535-1542
    CrossrefPubMedGoogle Scholar
  • 27 James S K, Armstrong P, Barnathan E. et al . Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome. A GUSTO-IV substudy.  J Am Coll Cardiol . 2003;  41 916-924
    CrossrefPubMedGoogle Scholar
  • 28 Venge P, Lagerqvist B, Diderholm E, Lindahl B, Wallentin L. Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy).  Am J Cardiol . 2002;  89 1035-1041
    CrossrefPubMedGoogle Scholar
  • 29 Morrow D A, Cannon C P, Rifai N. et al . Ability of minor elevations of troponin I and T to identify patients with unstable angina and non-ST elevation myocardial infarction who benefit from an early invasive strategy: results from a prospective, randomized trial.  JAMA . 2001;  286 2405-2412
    CrossrefPubMedGoogle Scholar
  • 30 Ohman E M, Armstrong P W, Christenson R H. et al . Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators.  N Engl J Med . 1996;  335 1333-1341
    CrossrefPubMedGoogle Scholar
  • 31 Ohman E M, Armstrong P W, White H D. et al . Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries.  Am J Cardiol . 1999;  84 1281-1286
    CrossrefPubMedGoogle Scholar
  • 32 Giannitsis E, Muller-Bardorff M, Lehrke S. et al . Admission troponin T level predicts clinical outcomes, TIMI flow, and myocardial tissue perfusion after primary percutaneous intervention for acute ST-segment elevation myocardial infarction.  Circulation . 2001;  104 630-635
    PubMedGoogle Scholar
  • 33 Kurowski V, Hartmann F, Killermann D P. et al . Prognostic significance of admission cardiac troponin T in patients treated successfully with direct percutaneous interventions for acute ST-segment elevation myocardial infarction.  Crit Care Med . 2002;  30 2229-2235
    PubMedGoogle Scholar
  • 34 Hamm C W, Heeschen C, Goldmann B. et al . Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) study investigators.  N Engl J Med . 1999;  340 1623-1629
    CrossrefPubMedGoogle Scholar
  • 35 Topol E J. Inflammation and embolization in ischemic heart disease.  J Invasive Cardiol . 2000;  12 (suppl B) 2B-7B
    PubMedGoogle Scholar
  • 36 Topol E J, Yadav J S. Recognition of the importance of embolization in atherosclerotic vascular disease.  Circulation . 2000;  101 570-580
    CrossrefPubMedGoogle Scholar
  • 37 Heeschen C, van Den Brand J M, Hamm C W, Simoons M L. Angiographic findings in patients with refractory unstable angina according to troponin T status.  Circulation . 1999;  100 1509-1514
    PubMedGoogle Scholar
  • 38 Wong G C, Morrow D A, Murphy S. et al . Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction.  Circulation . 2002;  106 202-207
    CrossrefPubMedGoogle Scholar
  • 39 Matetzky S, Sharir T, Domingo M. et al . Elevated troponin I level on admission is associated with adverse outcome of primary angioplasty in acute myocardial infarction.  Circulation . 2000;  102 1611-1616
    PubMedGoogle Scholar
  • 40 Morrow D A, Antman E M, Tanasijevic M. et al . Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI 11B substudy.  J Am Coll Cardiol . 2000;  36 1812-1817
    CrossrefPubMedGoogle Scholar
  • 41 Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group.  J Am Coll Cardiol . 1997;  29 43-48
    CrossrefPubMedGoogle Scholar
  • 42 Newby L K, Ohman E M, Christenson R H. et al . Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the paragon-B troponin T substudy.  Circulation . 2001;  103 2891-2896
    PubMedGoogle Scholar
  • 43 Januzzi J L, Chae C U, Sabatine M S, Jang I K. Elevation in serum troponin I predicts the benefit of tirofiban.  J Thromb Thrombolysis . 2001;  11 211-215
    CrossrefPubMedGoogle Scholar
  • 44 FRISC II Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study.  Lancet . 1999;  354 708-715
    CrossrefPubMedGoogle Scholar
  • 45 Akkerhuis K M, Alexander J H, Tardiff B E. et al . Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?.  Circulation . 2002;  105 554-556
    CrossrefPubMedGoogle Scholar
  • 46 Abdelmeguid A E, Topol E J, Whitlow P L, Sapp S K, Ellis S G. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions.  Circulation . 1996;  94 1528-1536
    PubMedGoogle Scholar
  • 47 Shyu K G, Kuan P L, Cheng J J, Hung C R. Cardiac troponin T, creatine kinase, and its isoform release after successful percutaneous transluminal coronary angioplasty with or without stenting.  Am Heart J . 1998;  135(5 Pt 1) 862-867
    PubMedGoogle Scholar
  • 48 Fuchs S, Gruberg L, Singh S. et al . Prognostic value of cardiac troponin I re-elevation following percutaneous coronary intervention in high-risk patients with acute coronary syndromes.  Am J Cardiol . 2001;  88 129-133
    CrossrefPubMedGoogle Scholar
  • 49 Bertinchant J P, Polge A, Ledermann B. et al . Relation of minor cardiac troponin I elevation to late cardiac events after uncomplicated elective successful percutaneous transluminal coronary angioplasty for angina pectoris.  Am J Cardiol . 1999;  84 51-57
    CrossrefPubMedGoogle Scholar
  • 50 Bonz A W, Lengenfelder B, Strotmann J. et al . Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial).  J Am Coll Cardiol . 2002;  40 662-668
    CrossrefPubMedGoogle Scholar
  • 51 Cantor W J, Newby L K, Christenson R H. et al . Prognostic significance of elevated troponin I after percutaneous coronary intervention.  J Am Coll Cardiol . 2002;  39 1738-1744
    CrossrefPubMedGoogle Scholar
  • 52 Wu A H, Boden W E, McKay R G. Long-term follow-up of patients with increased cardiac troponin concentrations following percutaneous coronary intervention.  Am J Cardiol . 2002;  89 1300-1302
    CrossrefPubMedGoogle Scholar
  • 53 Jaffe A S. Elevations in cardiac troponin measurements: false false positives.  Cardiovasc Toxicol . 2001;  1 87-92
    PubMedGoogle Scholar
  • 54 Mair J, Wohlfarter T, Koller A, Mayr M, Artner-Dworzak E, Puschendorf B. Serum cardiac troponin T after extraordinary endurance exercise.  Lancet . 1992;  340 1048
    PubMedGoogle Scholar
  • 55 Fitzmaurice T F, Brown C, Rifai N, Wu A H, Yeo K T. False increase of cardiac troponin I with heterophilic antibodies.  Clin Chem . 1998;  44 2212-2214
    PubMedGoogle Scholar
  • 56 Ricchiuti V, Voss E M, Ney A, Odland M, Anderson P A, Apple F S. Cardiac troponin T isoforms expressed in renal diseased skeletal muscle will not cause false-positive results by the second generation cardiac troponin T assay by Boehringer Mannheim.  Clin Chem . 1998;  44 1919-1924
    PubMedGoogle Scholar
  • 57 Morrow D A. Cardiac-specific troponins-beyond ischemic heart disease. In: Wu AH, ed. Cardiac Markers Totowa, NJ: Humana Press; 2003: 149-170
    Google Scholar
  • 58 Giannitsis E, Muller-Bardorff M, Kurowski V. et al . Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism.  Circulation . 2000;  102 211-217
    CrossrefPubMedGoogle Scholar
  • 59 Salim A, Velmahos G C, Jindal A. et al . Clinically significant blunt cardiac trauma: role of serum troponin levels combined with electrocardiographic findings.  J Trauma . 2001;  50 237-243
    PubMedGoogle Scholar
  • 60 Adams III E J, Davila-Roman V G, Bessey P Q, Blake D P, Ladenson J H, Jaffe A S. Improved detection of cardiac contusion with cardiac troponin I.  Am Heart J . 1996;  131 308-312
    CrossrefPubMedGoogle Scholar
  • 61 Apple F S, Murakami M M, Pearce L A, Herzog C A. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease.  Circulation . 2002;  106 2941-2945
    CrossrefPubMedGoogle Scholar
  • 62 Freda B J, Tang W H, Van Lente F, Peacock W F, Francis G S. Cardiac troponins in renal insufficiency: review and clinical implications.  J Am Coll Cardiol . 2002;  40 2065-2071
    CrossrefPubMedGoogle Scholar
  • 63 Aviles R J, Askari A T, Lindahl B. et al . Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction.  N Engl J Med . 2002;  346 2047-2052
    CrossrefPubMedGoogle Scholar
  • 64 Apple F S, Ricchiuti V, Voss E M, Anderson P A, Ney A, Odland M. Expression of cardiac troponin T isoforms in skeletal muscle of renal disease patients will not cause false-positive serum results by the second generation cardiac troponin T assay.  Eur Heart J . 1998;  19 (suppl N) N30-N33
    PubMedGoogle Scholar
  • 65 Missov E, Mair J. A novel biochemical approach to congestive heart failure: cardiac troponin T.  Am Heart J . 1999;  138 95-99
    PubMedGoogle Scholar